Plexiform neurofibroma mimicking a pancreatic cystic tumour

Pancreatic neurogenic tumours are extremely rare. Among benign neurogenic tumours, schwannoma is more frequently encountered. We report here the case of a plexiform neurofibroma, a type of neurogenic tumour in the pancreas, to our knowledge previously unreported.

History
A 44 year old Caucasian female patient was hospitalised for epigastric and right abdominal pain lasting for seven months. Abdominal ultrasound and computed tomography showed a cystic lesion located in the superior and anterior part of the pancreatic isthmus, with a maximal diameter of 3.5 cm (fig 1A, B). T2 magnetic resonance imaging demonstrated a trilobar cystic lesion with strong hyperintensity (fig 1B); no communication with the main pancreatic duct was noted at magnetic resonance cholangiopancreatography (fig 1C). Endoscopic ultrasound (EUS) showed a cystic lesion containing heterogeneous fluid (fig 1D). EUS guided fine needle aspiration provided mucoid fluid with no epithelial cells. Fluid pancreatic enzyme concentrations were 423 and 1204 U/l for amylase and lipase, respectively, while CEA, CA 19.9, and CA 72.4 were 17 ng/ml, 9 U/ml, and 140 U/ml, respectively. Despite the low CA 19.9 concentration and lack of mucinous cells in cystic fluid, other findings were consistent with a diagnosis of mucinous cystadenoma. Surgical exploration confirmed a cystic lesion of the superior part of the pancreatic isthmus, distant from the main pancreatic duct (fig 1A, B). Tumour enucleation was performed. On macroscopy there were a well delineated, trilobated, translucent mass, measuring 3.5 cm (fig 1E). The tumour consisted of aggregates of benign spindle cells embedded in a fibrillar matrix (fig 1F). These aggregates formed a rim around a large central low cellular zone of oedema and myxoid degeneration. The tumour cells expressed neurofilaments and S100 protein on immunohistochemistry. P53 immunostaining was negative and sparse nuclei were Ki67 positive. These features were consistent with a benign plexiform neurofibroma (PNF). No neurofibromatosis related lesions were found and no mutation of the NF1 (neurofibromatosis 1) gene was identified on analysis of DNA both from blood lymphocytes and tumour tissue. At follow up, two years after surgical resection, the patient did not present with any complaints and there was no evidence of pancreatic lesions.

Discussion
The presence of PNF in the pancreas has several clinical implications, as indicated by the present case. Firstly, PNF may mimic a pancreatic cyst, as was hypothesised in this case before surgery. The cystic appearance of neurogenic tumours is frequently encountered, with intratumoral oedematous and myxoid changes probably being the underlying lesions. A bright appearance on T2 weighted magnetic resonance imaging is a characteristic of PNF. Secondly, surgical
Resection was necessary to exclude malignancy which is more frequently encountered in PNF compared with classical neurofibromas. In addition to classical benign features, similar to published data on benign PNF, a high cell proliferation and p53 protein expression were absent in our case. Thirdly, PNF is a morphological variant of neurofibroma, generally considered pathognomonic for an NF1 syndrome. When diagnosed in adult patients, it is frequently a solitary tumour and is considered a mosaic located form of NF1 syndrome. The absence of detectable genetic abnormalities and other clinical NF1 syndrome associated lesions in the present case could be explained by such a mechanism. For these patients, there is a low risk of developing other diseases associated with NF1 syndrome.

In conclusion, we have reported an uncommon case of PNF, unique in its pancreatic location. Intratumoral myxoid and oedematous changes that develop in this type of neurofibroma give a cystic appearance which may lead to a misdiagnosis of a pancreatic cyst. Such lesions should be added to the list of benign pancreatic tumours with a cystic appearance.

A. Handra-Luca Department of Pathology, Jean Verdier and Beaujon Hospitals, Assistance Publique-Hôpitaux de Paris, France

D Vidaud Department of Biochemistry, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, France

M-P Vullierme Department of Radiology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, France

N Colnot Department of Pathology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, France

D Henin Department of Pathology, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, France

P Ruszniewski Department of Gastroenterology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, France

P Bedossa, A Couvelard Department of Pathology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, France

Correspondence to: Dr A Handra-Luca, MD PhD, Service d’Anatomie Pathologique, Assistance Publique-Hôpitaux Paris, Hôpital Jean Verdier, Avenue du 14 Juillet, 93143 Bondy, France. adriana.handra-luca@vrp.ap-hop-paris.fr
doi: 10.1136/gut.2005.074609
Conflict of interest: None declared.

References


6 McCarron KG, Golim JF. GAA form neurofibroma with and without associated malignant peripheral nerve sheath tumour: a clinicopatho-anatomical and immunohistochemical analysis of 54 cases. Mod Pathol 1998;11:612-17.


In a case control study on the associations between functional genetic polymorphisms in biotransformation enzymes and Crohn’s disease, we found a strong association between the Tyr113His (348T>G) polymorphism in exon 3 of the microsomal epoxide hydrolase (EPHX1) gene and Crohn’s disease. The three reference alleles agreed that the study was interesting and should be published so that other groups can attempt to replicate the results in independent study cohorts. This was done recently by Cuthbert and colleagues (Gut 2004;53:1386) who investigated 346 controls and 307 patients with Crohn’s disease, and who were unable to reproduce our results. In addition, they reported that our data for the EPHX1 exon 3 polymorphism in the control group were not in Hardy-Weinberg equilibrium (HWE), as also noticed previously by Györfy and colleagues. Our data on EPHX1 exon 3 genotyping were obtained by restricted fragment length polymorphism (RFLP) analyses by applying the method described by Lancaster and colleagues.

However, recently it was reported that a silent substitution polymorphism (G to A) at codon 119 of the EPHX1 gene may exist, which may distort the polymearse chain reaction (PCR) RFLP method applied by us, as the absence of this polymorphism may disturb proper binding of the reverse primer, covering the 119 G>A area, resulting in over-classification of His113 alleles. Therefore, we developed a dual colour allele specific discrimination assay for genotyping the polymorphism at codon 119 of the EPHX1 gene. EPHX1 genotypes were determined with the iCycler IQ Multicolour Real Time Detection System (Bio-Rad Laboratories, Veenendaal, the Netherlands) using molecular beacons. PCR was performed with the forward primer 5’-CAG TCT CCA TCA CTT CCT GAA G-3’ and the reverse primer 5’-TGA CAT ACA TCC TCT GTC G-3’ in the presence of the FAM labelled wild-type beacon (5’-CCG GAT GAT TCA CAG ATG CCG TCT GCG-3’) and the HEX labelled mutant beacon (5’-CCG GAT ATT CAC AGA CAC CCT CTC TAT GGC G-3’). The 25 µl reaction mixture contained 200 ng of genomic DNA, 10 mM Tris/HCl (pH 9.0), 50 mM KCl 0.1% Triton X-100, 4 mM MgCl2, 0.25 mM dNTPs, 50 ng of each primer, 200 mM of each buffer, and 2.5 U Taq-DNA polymerase. The PCR conditions were three minutes at 95°C, then 40 cycles of 30 seconds at 95°C, 30 seconds at 59°C, and 30 seconds at 72°C. Fluorescent signals were measured at 57°C, and the PCR-RFLP analyses were performed in the first half of 1999, only some of the samples were still available (125 of 149 controls and 149 of 151 cases) and these were re-evaluated by the Cycler method.

Genotype distribution of the EPHX1 Tyr113His polymorphism in patients with Crohn’s disease and controls was now in HWE (χ² = 1.7, p = 0.21 and χ² = 0.82, p = 0.37, respectively) and genotype distribution was not significantly different between cases and controls (χ² = 5.5, p = 0.17). The Tyr allele frequencies of 0.70 and 0.68 obtained for cases and controls, respectively, were similar to the corresponding values of 0.71 and 0.70, as reported by Cuthbert et al.

Thus in answer to the question as posed by Cuthbert et al: “Genetic association between EPHX1 and Crohn’s disease: population stratification, genotyping errors or random chance?”, we can conclude that a genotyping error was responsible for our earlier published association between the EPHX1 Tyr113His polymorphism and Crohn’s disease. Similar genotyping errors may also be present in several other studies on the EPHX1 exon 3 polymorphism in association with a variety of diseases, as many studies were based on methods using a reverse primer covering the “119 silent mutation area” of the EPHX1 gene. This may also have consequences for interpretation of results in the cited papers. However, a rapid literature search by Pubmed revealed more than 100 papers on EPHX1 polymorphisms over the past 10 years, suggesting that many more papers may deal with genotyping problems, as outlined above.

In addition, Cuthbert et al also reported that another polymorphism tested in our study, the CYP1A1 exon 7 Ile/Val polymorphism was not in HWE in the control group. This is correct but this deviation from HWE may be attributed to random chance, due to the rarity of the Val allele in our population, which makes the χ² test inappropriate under such conditions. For instance, genotype distribution is in accordance with HWE when only two individuals less would have been classified as Val/Val homozygotes.

We thank Cuthbert et al and Györfy and colleagues for their interest in our work. In addition, we conclude that (interpretation of) data in many other published studies on the EPHX1 Tyr113His (exon 3) polymorphism should be critically re-evaluated.

W H M Peters, E M J van der Logt, R H M te Morsche, H M J Roelofs, D J de Jong, T H J Naber Department of Gastroenterology, University Medical Centre Nijmegen, the Netherlands

Correspondence to: Dr W H M Peters, Department of Gastroenterology, University Medical Centre Nijmegen, PO Box 910, Nijmegen, the Netherlands. w.peters@mdl.umcn.nl
Conflict of interest: None declared.

www.gutjnl.com
Transcriptional downregulation of the lactase (LCT) gene during childhood

Adult-type hypolactasia, characterised by bloating, gas formation, and diarrhoea after ingestion of lactose containing food, affects half of the world’s population. The molecular background of lactase non-persistence/persistence trait has been shown to associate with a single nucleotide polymorphism (SNP) C/T at position 13910 residing 13910 base pairs upstream from the 5’ end of the lactase (LCT) gene in an intron of the minichromosome maintenance (MCM6) gene. We have demonstrated a trimodal distribution of lactase activity in the intestinal mucosa in adults, with low lactase activity (4–9 U/g protein) in those with the C/T 13910 genotype, mutations underlying congenital lactase deficiency (CLD) were screened for this patient and he was shown to be a carrier of a CLD mutation (unpublished data). Of the three subjects with the C.C 13910 genotype, the oldest subject aged 23 years had low lactase activity (6 U/g protein) as expected, the five year old subject had high lactase activity (24 U/g protein). Lactase mRNA was transcribed in a 1:1 ratio from the C. 13910 allele in children younger than five years of age. In children over six years of age, relative lactase mRNA expression from the C. 13910 allele was reduced to 18% and 16% compared with that from the T. 13910 allele (fig 1, table 1).

Our results show an increasing imbalance in relative mRNA expression between the C. 13910 and T. 13910 alleles in children aged >5 years. These results support the earlier findings on transcriptional regulation of the lactase gene and the finding in our own laboratory that the persistent T. 13910 allele was shown to represent a mean of 92% of expressed lactase mRNA in C/T 13910 heterozygous adults. The decline in lactase mRNA expression transcribed from the C. 13910 allele in the intestinal mucosa occurs in parallel with the time period of the decline in lactase enzyme activity, indicating a causative role for the intronic region containing the C. 13910 allele. Characterisation of the transcriptional regulators at the C/T 13910 enhancer element, and the exact mechanism underlying C. 13910 allele specific downregulation of lactase activity awaits elucidation.

Acknowledgements
We are grateful to the children and their families for their participation. Ms Sari Násman and Mervi Mänen from the Day Surgery Unit, Hospital for Children and Adolescents, are acknowledged for coordinating and managing the sample collection. Funding was provided by the Sigrid Juselius Foundation, Helsinki, Finland, the Helsinki University Hospital Research Funding, Helsinki, Finland, the Finnish Cultural Foundation, the Maud Kuistila Foundation, and The Research Foundation of Orion Pharma, Espoo, Finland.

H Rasinperä
Department of Medical Genetics, University of Helsinki, Finland

M Kuokkanen
Department of Medical Genetics, University of Helsinki, Finland, and National Public Health Institute, Department of Molecular Medicine, Helsinki, Finland

K-L Kolho, H Lindahl
Hospital for Children and Adolescents, University of Helsinki, Finland

N S Ennath
Department of Medical Genetics, University of Helsinki, Finland, and National Public Health Institute, Department of Molecular Medicine, Helsinki, Finland

E Savilahti
Hospital for Children and Adolescents, University of Helsinki, Finland

Table 1: Lactase activity, L/S ratio, and allelic ratio of the study subjects

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>C/T 13910 genotype</th>
<th>Lactase activity (U/g protein)</th>
<th>L/S ratio</th>
<th>Allele ratio (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8</td>
<td>CT</td>
<td>85</td>
<td>1.11</td>
<td>48/52</td>
</tr>
<tr>
<td>1.1</td>
<td>CT</td>
<td>113</td>
<td>1.02</td>
<td>52/48</td>
</tr>
<tr>
<td>4.0</td>
<td>CT</td>
<td>31</td>
<td>0.49</td>
<td>48/52</td>
</tr>
<tr>
<td>4.3</td>
<td>CT</td>
<td>53</td>
<td>0.48</td>
<td>42/58</td>
</tr>
<tr>
<td>4.7</td>
<td>CT</td>
<td>40</td>
<td>0.62</td>
<td>40/60</td>
</tr>
<tr>
<td>4.9</td>
<td>CT</td>
<td>6</td>
<td>0.08</td>
<td>48/52</td>
</tr>
<tr>
<td>5.1</td>
<td>CT</td>
<td>6</td>
<td>0.08</td>
<td>48/52</td>
</tr>
<tr>
<td>6.7</td>
<td>CT</td>
<td>22</td>
<td>0.28</td>
<td>18/82</td>
</tr>
<tr>
<td>7.6</td>
<td>CT</td>
<td>29</td>
<td>0.54</td>
<td>13/87</td>
</tr>
<tr>
<td>11.1</td>
<td>CT</td>
<td>29</td>
<td>0.62</td>
<td>24/76</td>
</tr>
<tr>
<td>14.9</td>
<td>CT</td>
<td>29</td>
<td>0.62</td>
<td>24/76</td>
</tr>
<tr>
<td>17.0</td>
<td>CT</td>
<td>29</td>
<td>0.62</td>
<td>24/76</td>
</tr>
<tr>
<td>1.1</td>
<td>CT 13910</td>
<td>24</td>
<td>0.28</td>
<td>51/49</td>
</tr>
<tr>
<td>5.0</td>
<td>CT</td>
<td>6</td>
<td>0.08</td>
<td>49/51</td>
</tr>
</tbody>
</table>

*Defined by assessing cSNP G/A 593 in exon 1 of the lactase LCT gene.
†Carrier of a CLD mutation (unpublished data).
Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma

Pancreatic adenocarcinoma is the fourth leading cause of cancer death in the USA. Although predominantly a cancer of the elderly, approximately 20% of patients are diagnosed under the age of 60 years. Younger patients are likely the best candidates for early surgical intervention, and patients at risk for young onset cancer comprise a logical focus for screening or prevention.

Carriers of mutations in the gene that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) are associated with chronic idiopathic pancreatitis. Chronic pancreatitis, in turn, increases the risk for pancreatic cancer by 26-fold. Therefore, we hypothesised that mutations in CFTR may confer a higher risk of pancreatic cancer.

From October 2000 to April 2004, pancreatic cancer patients seen at the Mayo Clinic were ultra rapidly recruited to our study, with more than 75% of all such patients seen at the Mayo Clinic enrolled in the registry. This represents a substantial improvement over population based pancreatic cancer epidemiological studies, with participation rates ranging from 34.6% to 45.6%. Informed written consent and institutional review board approval were obtained.

As a pilot study, 33 patients were selected in whom a pathological diagnosis of pancreatitis was noted at the time of pancreatic cancer surgery. The patients ranged in age from 41 to 81 years (median 65), and seven of the 33 had a diagnosis of pancreatitis made at least one year prior to cancer diagnosis. These patients were screened for variants in CFTR using the Taq-It Mutation Detection Kit, a clinically available kit testing for 40 mutations.

Of 33 samples tested, two patients (6%) were noted to have mutations in CFTR, both of which were the most common mutation identified in the CFTR gene, AF508. Both patients had young onset disease (ages 42 and 50 years). In total, seven patients in our pilot sample were below the age of 60 years, making the carrier rate 29% in this young onset subgroup.

Therefore, we designed a larger study to test the remainder of young onset cases in our registry, comprising a sequential unsel ected sample for mutations in CFTR (Cystic Fibrosis v3.0 ASR, Celera/Abbott), totalling 166 patients under the age of 60 years. Smoking status and family history were obtained from questionnaires. Personal history of chronic pancreatitis was identified by a single physician review of the medical records.

For a comparison group, the clinical database of CFTR analyses performed at the Mayo Clinic from November 2003 to May 2004 was utilised. Ethnic composition of cases and controls were highly comparable.

As shown in table 1, 14 of the 166 (8.4%) young onset pancreatic cancer cases were carriers for CFTR mutations, compared with 217 of 5349 (4.1%) patients in our control database (p = 0.006, odds ratio 2.18 (95% confidence interval 1.24–3.29)). There was no significant difference in age of onset, pancreatitis, family history of pancreatic cancer, or smoking in carriers versus non-carriers of CFTR mutations.

Several cases of patients with cystic fibrosis (CF) and pancreatic adenocarcinoma have been reported, and two cohort studies have shown an increased risk for pancreatic cancer among CF homozygotes. Two studies have investigated CFTR mutation frequencies in pancreatic cancer patients, with negative results. However, both series only investigated one mutation (AF508), and neither focused on young onset patients.

Our study represents the first positive association of pancreatic cancer risk with CFTR carrier status, with mutations conferring a twofold risk for cancer before the age of 60 years. The finding that only one of the CFTR carriers had an antecedent history of pancreatitis is intriguing, as either pancreatitis is subclinical or the presence of one mutant CFTR allele may increase the risk for pancreatic cancer through a mechanism independent of chronic pancreatitis. A larger study to confirm these results is ongoing.

Acknowledgements

We thank the patients in this study and the contributions of Tammy Dahl, RN, Kathy L firefight, Cynthia Nixa, Diane Batzel, Que Luan, Suresh Chari, MD, and Thomas Smyrk, MD.

Funding for this research was provided by the Mayo Clinic SPORE in Pancreatic Cancer (PS0 CA 102701), R25T CA 92049, Lustgarten Foundation for Pancreas Cancer Research, NCI GRANT (R01 CA97075).

R McWilliams
Department of Oncology and Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

W E Highsmith
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

K G Rabe, M de Andrade, L A Tordsen
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
Distal intestinal obstruction syndrome in the early postoperative period after lung transplantation in a patient with cystic fibrosis: morphological findings on computed tomography

Distal intestinal obstruction syndrome (DIOS) occurs in 19.9% of adults with cystic fibrosis (CF). Usually the diagnosis is based on history, physical examination, and plain abdominal roentgenogram. The increased risk of gastrointestinal complications such as DIOS is well known after lung transplantation. Due to the added risk of gastrointestinal surgery in the postoperative period and the generally good response to conservative treatment, it is necessary to distinguish DIOS from other gastrointestinal complications. Nevertheless, descriptions of computed tomographical patterns of DIOS in the international literature are rare.

We present the case of a 34 year old male suffering from end stage CF. Because of gastrointestinal manifestations of CF, the patient had exocrine pancreas insufficiency. As a consequence of deterioration in respiratory function, lung transplantation was performed. Despite enzymatic and propulsive medical treatment the patient developed an acute abdomen during the postoperative period. To determine the cause of his symptoms abdominal radiographs and computed tomography were performed. Abdominal plain films showed remarkably little abdominal gas and poor delineation of the abdominal organs (fig 1A). Contrast enhanced computed tomography showed massive dilatation of the small bowel and proximal colon with marked swelling of the intestinal wall (fig 1B, C). The lumen of the small intestine and proximal part of the ascending colon were filled with a homogenous mass (fig 1B) with increasing roentgen opacity from the duodenum (approximately 19 Hounsfield units) to the right hemicolon (approximately 39 HU). Isolated air fluid levels were seen in the small bowel. The transverse, descending, and sigmoid colon were thin with only little faeces. There was no evidence of external compression. Based on these findings a diagnosis of DIOS was made. Laparotomy, performed due to failure of medical treatment, confirmed the diagnosis.

DIOS is unique to patients with cystic fibrosis. Intestinal obstruction developed due to accumulation of highly viscous mucous faeces. This occurred due to the high viscosity of the intestinal content. The accumulation of intraluminal macromolecules, dehydration of the mucus layer and of ulcers and僕to the right hemicolon. In accordance with previous descriptions of DIOS, obstruction occurred in the right hemicolon.

Our case showed that abdominal plain films, as used in previous studies, are not adequate for the diagnosis of DIOS. Computed tomography can reveal the characteristic signs of DIOS and exclude inherent differential diagnoses. We have demonstrated for the first time that DIOS causes increasing opacity of intestinal contents during small intestinal passage, suggesting increasing viscosity.

References
Association of a new cationic trypsinogen gene mutation (V39A) with chronic pancreatitis in an Italian family

Predilection to hereditary pancreatitis has been associated with mutations in three genes: protease, serine, 1 (PRSS1), which codes for cationic trypsinogen, three cystic fibrosis transmembrane conductance regulator (CFTR), and serine protease inhibitor Kazal type 1 (SPINK1).

We have identified a novel PRSS1 mutation in seven subjects with chronic pancreatitis (CP) from three generations of an Italian family. The index patient was a 57 year old man with CP referred to our hospital for duodenal adenocarcinoma of the pancreatic head. Eleven relatives were examined, and an uncle, also with CP, had died in an accident.

Congenital malformations and alcoholic, biliary, obstructive, and autoimmune pancreatitis were ruled out. Eleven subjects gave their written consent to the study.

The cystic fibrosis assay (CF-OLA; Applied Biosystems, California, USA) was used to confirm the diagnosis of cystic fibrosis. The remaining four subjects had a normal pancreas and did not carry the V39A mutation (fig 1).

The lod score calculated for the association between V39A and CP was z = 3.0 at q = 0.0. This mutation was not found in a DGGG investigation of 130 patients with sporadic CP.

Mean age of the patients was 47.22 (±13.64) years (median 34 (range 25–60)). Mean age at onset was 30.0 (±7.35) years (median 32 (range 19–40)) whereas in patients displaying other PRSS1 mutations, onset was typically during childhood or adolescence.

An acute attack requiring hospitalisation formed the clinical overtone in six of the nine CP patients. The other three (II-4, III-5 and IV-2) presented morphological and functional evidence of CP at the time of the study but were asymptomatic. It is clear therefore that damage to the pancreas may occur prior to the clinical onset of CP.

In hereditary CP, the mechanism of the R122H mutation has been elucidated. This mutation removes a hydrolysis start site and makes both trypsin and trypsinogen autoproteolytically resistant. A similar mechanism has been proposed for the N29I mutation which alters protein conformation and masks the R122 site.

Valine 39 is evolutionarily conserved in the trypsinogen gene of all terrestrial vertebrates and would thus seem of importance in the protein’s structure and function. As V39 is only 10 amino acids distant from N29, its replacement by alanine may result in abnormal conformation of the peptide and mask arginine 122 against enzymatic degradation. Further work is needed to define the mechanism and confirm this interpretation.

In conclusion, the presence of the V39A mutation in seven of the CP patients, its absence in their healthy relatives, the 3.0 lod score, and strong evolutionary conservatism of V39, all indicate that the novel mutation is the cause of CP in this family.

Acknowledgements

We would like to thank Professors JP Neoptolemos and DC Whitcomb for their valuable assistance and Mr J Iliffe. This work was supported by Compagnia di San Paolo and Regione Piemonte.

C Arduino
SC Genetica Medica, ASOS Giovanni Battista, Torino, Italy

P Salacone
SC Gastroenterologia, ASO San Luigi Gonzaga, Orbassano (TO), Italy

B Pasini, A Brusco
Università di Torino, Dipartimento di Genetica, Biologia e Biochimica, Torino, Italy

Figure 1  Pedigree showing the age of subjects, and for those with pancreatitis (black symbols) their age at onset (where known). WT, wild-type (that is, subjects without pancreatitis and without the V39A mutation); black triangle, index patient; ?, no clinical or genetic data available.

www.gutjnl.com
ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients

We read with interest the letter by Colombel et al on the non-predictive value of ITPA genotyping for the development of myelosuppression after azathioprine (AZA) treatment (Gut 2005;54:565).

The level of thiopurine methyltransferase (TPMT) activity is determined by a common genetic polymorphism. It was shown that low TPMT activity is linked to a higher relative risk of development of myelosuppression after AZA treatment.1 Testing for TPMT genotype before the start of AZA treatment is of limited clinical value as myelosuppression resulting from TPMT mutations occurs in less than one third of patients with myelosuppression.

Polymorphisms in genes encoding inosine triphosphate pyrophosphatase (ITPase), another enzyme involved in metabolism of AZA, have also been suggested to be associated with the development of side effects in AZA treatment.2 Colombel et al showed that there was no difference in the frequency of ITPA polymorphisms in 41 patients who developed AZA related myelosuppression in comparison with a previously published control population.3 Unfortunately, this leaves the question of other side effects such as flu-like symptoms, rash, and pancreatitis unanswered. In addition to the TPMT polymorphism, we determined the 94C>A ITPA polymorphism. All (109) patients with inflammatory bowel disease who started AZA treatment from January 2003 onwards were included, and side effects were determined. There was a mean follow up time of 13 months (range 4–24). The frequency of side effects was compared with the frequency of side effects in AZA treated patients without any ITPA polymorphism. Notably, for patients with a heterogenous TPMT or ITPA polymorphism, no preventive adjustments of AZA dosing were made.

In a patient group of a total of 109 patients, we found 10 who had a TPMT polymorphism and 12 who had a 94C>A ITPA polymorphism. Eighty eight patients had none of the studied polymorphisms in TPMT or ITPA genes. Of the 12 patients who had an ITPA heterozygous polymorphism only two had side effects (17%). One had a rash and the other had complaints of arthralgia. In patients without any of the investigated polymorphisms, 34 of 88 (39%) had side effects (summarised in table 1). There was one patient, receiving a normal dose of AZA, who had both a TPMT*5A and an ITPA 94C>A heterozygous polymorphism. Interestingly, this patient did not develop any side effects.

Our data confirms the results of Colombel’s research by showing that an ITPA heterozygous polymorphism is not associated with an increased risk for the development of leucopenia. Additionally, we also found that there was no increased risk for the development of other side effects.

No conclusions can be drawn for patients who are homozygous for the ITPA 94C>A polymorphism as none was included either in our study or in Colombel’s. Marinaki et al included three patients with a homozygous 94C>A polymorphism for ITPA and all three had side effects.4 Therefore, further research on the risk of developing side effects in homozygous 94C>A ITPA patients is desirable.

References


Table 1 Side effects in 109 azathioprine treated inflammatory bowel disease patients related to their thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) genotypes

<table>
<thead>
<tr>
<th>Side effect</th>
<th>No polymorphisms (88 of 109)</th>
<th>TPMT polymorphisms (10/109)</th>
<th>ITPA polymorphisms (12 of 109)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1/1*3A</td>
<td>1/1<em>1C</em>3A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Leucocytopenia &lt; 2 x 10^9/l</td>
<td></td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Leucocytopenia 2-4 x 10^9/l</td>
<td></td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Hepatotoxicity</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Gastrintestinal</td>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>8</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>88</td>
<td>7</td>
<td>1</td>
</tr>
</tbody>
</table>

One patient was included in both the TPMT polymorphisms column and in the ITPA polymorphisms column as he was heterozygous for the TPMT*3A polymorphism and heterozygous for the ITPA 94C>A polymorphism. Side effects categorised as “other” included rash, renal function disorders, vertigo, myalgia, and arthralgia.
Lack of serum antibodies to membrane bound carbonic anhydrase IV in patients with primary biliary cirrhosis

Nishimori et al have recently reported the presence of autoantibodies against carbonic anhydrase IV (anti-CA IV) in patients with autoimmune pancreatitis (Gut 2005;54:274–81). Furthermore, serum antibodies to CA II (anti-CA II) were observed in several autoimmune conditions. We have now investigated the presence of anti-CA IV and anti-CA II in a large series of sera from patients with primary biliary cirrhosis (PBC) and controls. CA II is known to be expressed in the cytoplasm of various types of epithelial cells, including those lining bile ducts, renal tubules, and salivary ducts. For this reason, CA II was suggested as a common antigen in conditions characterised by an autoimmune aggression against epithelia. In autoimmune pancreatitis, serum anti-CA II are useful diagnostic tools while in PBC they were first detected by Gordon et al in 5/6 sera from patients with antimitochondrial antibody (AMA) positive PBC. Subsequent studies however demonstrated prevalence rates as high as 46% in PBC sera but failed to confirm their specificity for AMA negative sera.1,2 Interestingly, anti-CA II were also shown to inhibit enzyme activity.3

Apart from cytosolic CA II, the CA family also includes a highly active membrane bound enzyme that was coined CA IV.4 Both CA II and CA IV are abundantly expressed in human bile duct epithelial cells. Interestingly, mainly due to the sequence homology between CA II and CA IV and CA IV localisation on cell membranes, Nishimori et al hypothesised that the exposed CA IV might be more immunogenic than cytosolic CA II.5 Seventy sera from patients with PBC (60 AMA positive; all anti-hepatitis C virus negative; 63 women; mean age 60 (SD 10) years) who attended our tertiary referral centre were consecutively enrolled in the study. Control sera were obtained from 50 healthy subjects matched with patients for sex and age class (<50 v >50 years). All sera were tested by immunoblotting for anti-CA IV and anti-CA II as previously described.6 Briefly, proteins were denatured and separated (10 µg/lane) on a 1.5 mm sodium dodecyl sulphate-12% polyacrylamide gel. Proteins were then transferred onto nitrocel- lulose (pore size 0.45 mm) using a semi-dry transfer system. The nitrocellulose membrane was cut into 4 mm strips and, after blocking with 5% non-fat milk, all strips were incubated with serum samples diluted 1:100 and 1:1000 and 1:1000 for anti-CA II. Rabbit horseradish peroxidase conjugated antibodies against human immunoglobulins G, A, and M (Dako, Glostrup, Denmark) was used as a secondary antibody. Peroxidase development was obtained with 0.05% 4-chloro-1-naphthol in Tris buffered saline containing 20% methanol and 0.05% H2O2. A rabbit polyclonal antihuman CA IV antisera was used as a positive control throughout the study. CA IV antibody and anti-CA IV antisera were provided by Dr William S Sly (St. Louis, Missouri, USA). Results demonstrated no reactivity against CA IV in any of the PBC or healthy control sera. In similar to previous reports, anti-CA II antibodies were detected in 670/ (9%) sera from patients with PBC but were absent in control sera.

In summary, we submit that the hypothesis that antibodies against the membrane bound CA IV may play a role in PBC should be rejected. Based on our experimental data, we conclude that CA II is a more immunogenic than cytosolic CA II. The presence of autoantibodies against human immunoglobulins was cut into 4 mm strips and, after blocking transfer system. The nitrocellulose membrane was used as a positive control. Anti-CA II antibodies against human immunoglobulins was cut into 4 mm strips and, after blocking transfer system. The nitrocellulose membrane was used as a positive control.

References


Conflict of interest: None declared.

www.gutjnl.com

Gut: first published as 10.1136/gut.2005.072389 on 13 October 2005. Downloaded from http://gut.bmj.com/ on September 16, 2023 by guest. Protected by copyright.
New Techniques in Gastrointestinal Imaging


Many areas of radiology are rapidly developing new techniques to answer clinical problems or devising ways of refining current imaging techniques. Gastrointestinal imaging is no exception.

New Techniques in Gastrointestinal Imaging has been edited and written by experts in the field from the international community and encompasses the more recent developments in all aspects of gastrointestinal imaging. The book has been divided into chapters that either concentrate on a particular imaging technique (for example, computed tomography (CT) colonography) or those that cover recent developments in the investigation of a particular area (for example, the rectum). There are very comprehensive chapters covering the new CT and magnetic resonance (MR) techniques available for imaging the colon and small bowel. New CT and MR techniques for hepatic imaging are also included, with special reference to the development of CT angiography. There are excellent chapters on the use of microbubbles in ultrasound (US) and endoscopic US, both of which are good introductions to these techniques for those with limited previous knowledge or experience. Also included is a very useful chapter on positron emission tomography (PET) with a gentle introduction to the physics of the technique and current applications and limitations. New interventional imaging techniques are also covered, with chapters on radiofrequency ablation of liver lesions and on self expanding metallic stents in the colon.

I was however dismayed to find a section on defecating proctography, a technique I had rather hoped had been consigned to the barium room although new MR techniques are described.

This book has been written to update the general radiologist in areas of gastrointestinal radiology that have changed significantly in recent times. This it does very well, with concise descriptions of the techniques, thorough discussions on clinical use, and handy tips on image interpretation. As such, there are chapters in the book that need some background knowledge of radiological techniques to appreciate the new developments (for example, CT and MR chapters on liver imaging). However, all chapters provide a good setting for each of the new techniques so that the interested gastroenterologist would find useful information on the current role of each investigation, its performance with relation to more established techniques, and future developments.

A Graham

CORRECTIONS

doi: 10.1136/gut.2005.064824

In the Editor’s quiz: GI snapshot on p1272 of the September issue (D Joshi, J Dunga, A James and MM Yaqoob. An unusual case of hepatosplenomegaly. Gut 2005;54:1272; doi:10.1136/gut.2005.064824) the second author’s name should read Dungu not Dunga.

In the Gut Tutorial on p296 of the February issue the author’s name and affiliation was omitted. The details are as follows: Robin Spiller, Professor of Gastroenterology, Wolfson Digestive Diseases Centre, University Hospital, Nottingham NG7 2UH, UK.

In the Gut Tutorial on p555 of the May issue the author names and affiliations were omitted from the original publication. This has been updated on the Gut website. The authors and affiliations are as follows:

S A Khan, A Miras, Liver Unit, Department of Medicine A, Faculty of Medicine, Imperial College London, St Mary’s Hospital Campus, South Wharf Road, London W2 1NY, UK; M Pelling, Department of Radiology, Faculty of Medicine, Imperial College London; S D Taylor-Robinson, Liver Unit, Department of Medicine A, Faculty of Medicine, Imperial College London.